Abstract
The five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) remains only 10%, urging the development of novel therapeutics and combination therapies. Immune checkpoint blockade (ICB) and virotherapy have improved survival for a subset of cancer patients in recent years. However, extending the benefit to patients with PDAC has lagged. Prior studies have highlighted the role of intact type I interferon (IFN) signaling in mediating PDAC resistance to oncolytic vesicular stomatitis virus (VSV).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
